2,016 Shares in AbbVie Inc. (NYSE:ABBV) Acquired by Hopwood Financial Services Inc.

Hopwood Financial Services Inc. bought a new stake in AbbVie Inc. (NYSE:ABBV - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 2,016 shares of the company's stock, valued at approximately $358,000.

A number of other large investors also recently added to or reduced their stakes in ABBV. Knuff & Co LLC grew its position in AbbVie by 1.5% in the 4th quarter. Knuff & Co LLC now owns 7,894 shares of the company's stock valued at $1,403,000 after acquiring an additional 119 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in AbbVie by 11.5% during the 4th quarter. EverSource Wealth Advisors LLC now owns 10,818 shares of the company's stock worth $1,922,000 after buying an additional 1,119 shares during the period. Sequoia Financial Advisors LLC grew its stake in shares of AbbVie by 1.7% in the fourth quarter. Sequoia Financial Advisors LLC now owns 69,595 shares of the company's stock worth $12,367,000 after acquiring an additional 1,146 shares in the last quarter. HighTower Advisors LLC raised its stake in shares of AbbVie by 6.8% in the fourth quarter. HighTower Advisors LLC now owns 1,573,829 shares of the company's stock valued at $279,669,000 after acquiring an additional 100,418 shares in the last quarter. Finally, Windle Wealth LLC boosted its holdings in AbbVie by 4.7% in the fourth quarter. Windle Wealth LLC now owns 41,022 shares of the company's stock valued at $7,290,000 after purchasing an additional 1,854 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ABBV. Morgan Stanley lifted their price target on shares of AbbVie from $224.00 to $239.00 and gave the stock an "overweight" rating in a research note on Monday, February 3rd. UBS Group raised their price target on AbbVie from $181.00 to $190.00 and gave the company a "neutral" rating in a research note on Monday, February 3rd. Piper Sandler raised their target price on AbbVie from $212.00 to $220.00 and gave the stock an "overweight" rating in a research report on Tuesday, December 17th. Leerink Partnrs raised shares of AbbVie from a "hold" rating to a "strong-buy" rating in a report on Friday, November 22nd. Finally, Raymond James restated an "outperform" rating and issued a $220.00 target price (up previously from $218.00) on shares of AbbVie in a report on Monday, February 3rd. Five equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, AbbVie has a consensus rating of "Moderate Buy" and an average target price of $211.45.

Remove Ads

Insider Transactions at AbbVie

In other news, SVP Kevin K. Buckbee sold 1,800 shares of AbbVie stock in a transaction on Monday, December 16th. The stock was sold at an average price of $172.24, for a total value of $310,032.00. Following the completion of the sale, the senior vice president now owns 6,983 shares of the company's stock, valued at $1,202,751.92. The trade was a 20.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Timothy J. Richmond sold 29,917 shares of the firm's stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $202.90, for a total value of $6,070,159.30. Following the completion of the sale, the executive vice president now directly owns 44,284 shares in the company, valued at approximately $8,985,223.60. The trade was a 40.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 56,439 shares of company stock worth $11,377,057 over the last ninety days. 0.25% of the stock is currently owned by corporate insiders.

AbbVie Price Performance

Shares of NYSE ABBV opened at $213.71 on Wednesday. The company has a current ratio of 0.66, a quick ratio of 0.55 and a debt-to-equity ratio of 17.94. The company's 50-day moving average price is $189.16 and its 200 day moving average price is $187.73. AbbVie Inc. has a 52 week low of $153.58 and a 52 week high of $218.66. The stock has a market cap of $377.28 billion, a price-to-earnings ratio of 89.05, a PEG ratio of 1.62 and a beta of 0.61.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings data on Friday, January 31st. The company reported $2.16 earnings per share for the quarter, missing analysts' consensus estimates of $2.98 by ($0.82). AbbVie had a return on equity of 296.28% and a net margin of 7.59%. During the same quarter in the previous year, the firm earned $2.79 EPS. As a group, research analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be issued a $1.64 dividend. The ex-dividend date is Tuesday, April 15th. This represents a $6.56 dividend on an annualized basis and a yield of 3.07%. AbbVie's dividend payout ratio (DPR) is 273.33%.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.